Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors

J Med Chem. 2009 Mar 26;52(6):1681-92. doi: 10.1021/jm801427r.


A number of pyrazolo[3,4-d]pyrimidin-4-ones bearing either alkyl or arylalkyl substituents in position 2 of the nucleus were synthesized and tested for their ability to inhibit adenosine deaminase (ADA) from bovine spleen. The 2-arylalkyl derivatives exhibited excellent inhibitory activity, showing Ki values in the nanomolar/subnanomolar range. The most active compound, 1-(4-((4-oxo-4,5-dihydropyrazolo[3,4-d]pyrimidin-2-yl)methyl)phenyl)-3-(4-(trifluoromethyl)phenyl)urea, 14d, was tested in rats with colitis induced by 2,4-dinitrobenzenesulfonic acid to assess its efficacy to attenuate bowel inflammation. The treatment with 14d induced a significant amelioration of both systemic and intestinal inflammatory alterations in animals with experimental colitis. Docking simulations of the synthesized compounds into the ADA catalytic site were also performed to rationalize the structure-activity relationships observed and to highlight the key pharmacophoric elements of these products, thus prospectively guiding the design of novel ADA inhibitors.

MeSH terms

  • Adenosine Deaminase Inhibitors*
  • Animals
  • Catalytic Domain
  • Colitis / drug therapy
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use
  • Pyrazoles / chemistry*
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use
  • Pyridines / chemistry*
  • Pyridines / pharmacology*
  • Pyridines / therapeutic use
  • Rats
  • Structure-Activity Relationship


  • Adenosine Deaminase Inhibitors
  • Enzyme Inhibitors
  • Pyrazoles
  • Pyridines
  • pyrazolo(3,4-b)pyridine